XENE Insider Trading

Xenon Pharmaceuticals Inc. (XENE) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $3.98B, listed on NASDAQ, employing roughly 364 people, carrying a beta of 0.60 to the broader market. Xenon Pharmaceuticals Inc. Led by Ian C. Mortimer, public since 2014-11-05.

In the last 12 months, Xenon Pharmaceuticals Inc. insiders made 2 buy transactions and 26 sale transactions.

DateNameTypeSharesPriceValue
Oct 16, 2026Kelly Thomas PatrickM-Exempt7,500$0.00$0
Oct 16, 2026Kelly Thomas PatrickM-Exempt7,500$0.00$0
Oct 1, 2026Kelly Thomas PatrickP-Purchase15,000$37.32$559.7K
Oct 1, 2026MORTIMER IANP-Purchase30,000$37.38$1.1M
Sep 3, 2026Svoronos DawnM-Exempt5,144$8.15$41.9K
Sep 3, 2026Svoronos DawnM-Exempt5,144$8.15$41.9K
Aug 31, 2026KENNEY CHRISTOPHER JOHNS-Sale6,368$60.17$383.1K
Aug 31, 2026KENNEY CHRISTOPHER JOHNS-Sale700$60.98$42.7K
Aug 13, 2026GANNON STEVENS-Sale10,000$64.06$640.6K
Jun 8, 2026PATOU GARYS-Sale1,322$53.14$70.3K

XENE Insider Activity by Quarter

Reported Form 4 and Form 5 lines under XENE's own SEC company ID, by transaction date, back to Q4 2024. Purchases and sales are code P / S (open market or private) in the company's shares; other lines are purchases and sales of other securities (options, warrants, preferred), awards, exercises, tax withholding, gifts and other acquisitions and dispositions. Later filings and amendments can change the current quarter. Earlier quarters are not shown: the filings read reach back to Dec 26, 2018, and a quarter counts only when every filing for it was read. Last refreshed Nov 9, 2026.

QuarterPurchasesBoughtSalesSoldOther Lines
Q4 2026 (so far)0N/A0N/A2
Q3 20262$1.7M3$1.1M2
Q2 20260N/A2$133.5K32
Q1 20260N/A17$19.6M33
Q4 20250N/A5$2.2M4
Q3 20250N/A0N/A0
Q2 20250N/A1$9117
Q1 20250N/A4$2.2M13
Q4 20240N/A4$971.9K12

XENE Institutional Ownership (13F)

As of Jun 30, 2026 (Q2 2026), 315 institutions reported holding 101,110,526 XENE shares, valued at $6.10B as reported, 116.9% of its market cap (market cap of Jun 26, 2026). That is +25 institutions from the quarter before. Among managers whose reports for both quarters are comparable, 45 opened a position, 19 closed one, 125 added and 87 trimmed.

Top Holders, Q2 2026

ManagerSharesValueChange
FMR LLC9,647,998$582.4M-1,170,493
BlackRock, Inc.7,522,482$454.1M+1,882,364
Avoro Capital Advisors LLC5,777,777$348.7MUnchanged
Polar Capital Holdings Plc4,570,556$275.9M+165,244
Driehaus Capital Management LLC4,418,557$266.7M-73,096
Jupiter Topco LLC4,186,519$252.7MNo comparable report
PRICE T ROWE ASSOCIATES INC /MD/3,248,219$196.1M+1,918,628
JPMORGAN CHASE & CO2,617,360$157.4M+693,750
Capital International Investors2,361,639$142.5M-313,088
T. Rowe Price Investment Management, Inc.2,168,581$130.9M+1,216,626

By Quarter

QuarterInstitutionsSharesValue
Q2 2026315101,110,526$6.10B
Q1 2026290100,388,661$5.81B
Q4 202524684,572,434$3.79B
Q3 202521985,719,863$3.44B
Q2 202520683,278,331$2.61B
Q1 202520676,774,061$2.58B
Q4 202420976,311,942$2.99B
Q3 202420175,851,674$2.99B
Q2 202421175,226,749$2.93B

From the SEC's Form 13F data sets: investment managers with $100 million or more in Section 13(f) securities report their holdings each quarter, up to 45 days after it ends; a restated filing replaces the original, and values are as the managers reported them (a position whose price runs about 1,000 times below other managers', from a manager whose positions mostly do, is read as reported in thousands of dollars). The same shares can be reported by more than one manager, so totals can count some twice.

ETFs Holding XENE

FundWeight of XENEShares (as reported)Value (as reported)Source updated
IWM iShares Russell 2000 ETF0.14%2,540,886$107.0MNov 12, 2026
IWO iShares Russell 2000 Growth ETF0.27%926,341$39.0MNov 12, 2026
IBB iShares Biotechnology ETF0.26%708,009$29.8MNov 12, 2026
TCAF T. Rowe Capital Appreciation Equity ETF0.31%627,488$26.4MNov 13, 2026
VTWO Vanguard Russell 2000 ETF0.12%570,640$21.2MNov 12, 2026
SPDW State Street SPDR Portfolio Developed World ex-US ETF0.02%157,391$6.6MNov 12, 2026
FESM Fidelity Enhanced Small Cap ETF0.09%143,466$6.0MNov 13, 2026
SBIO ALPS Medical Breakthroughs ETF2.60%118,559$4.9MNov 13, 2026
TMSL T. Rowe Price Small-Mid Cap ETF0.12%96,479$4.1MNov 13, 2026
VTWG Vanguard Russell 2000 Growth ETF0.24%106,933$4.0MNov 12, 2026
ESML iShares ESG Aware MSCI USA Small-Cap ETF0.12%81,324$3.4MNov 12, 2026
NUSC Nuveen ESG Small-Cap ETF0.26%81,582$3.3MNov 13, 2026
VT Vanguard Total World Stock ETF0.00%81,475$3.0MNov 12, 2026
RSSL Global X - Russell 2000 ETF0.14%47,053$2.0MNov 12, 2026
FHLC Fidelity MSCI Health Care Index ETF0.04%42,909$1.8MNov 13, 2026

From each fund's latest holdings file on record that shows XENE's listed security itself. A file counts when its line count is consistent with the fund's reported holdings count (at most twice it plus 10, or at most 1,000 lines for a reported count of exactly 10, which the data source gives many funds as a cap), read with that file or inherited from the fund's last classified file (within 20% of its line count, read within 60 days). Funds whose line for the company could not be confirmed as XENE's listed security, or that hold it through underlying funds (look-through), are not listed. Only long positions count: a fund is left out when any of its lines for XENE reports a negative weight, share count or value, or none of them above zero (a short position, or figures that disagree). Shares, value and weight are as reported in each fund's file, dated by the data source's last update of that file (not the date of the positions); the weight is XENE's share of that fund.

How to Read XENE Insider Activity

Net insider sentiment skews to the sell side over the trailing twelve months: 26 sales versus 2 buys. Insider sales carry less informational weight than buys because they are often driven by liquidity, tax planning, or pre-scheduled Rule 10b5-1 trading plans rather than negative information. The transaction type alone does not say whether a sale was made on the open market or privately, or under a 10b5-1 plan; the filing's plan checkbox and footnotes do. The transaction table above includes the filer's reporting name, transaction type, share count, per-share price, and total dollar value where computable. For options traders, insider activity is one input to event-driven sizing alongside earnings calendar, analyst-rating cluster moves, and the implied-vol surface. Form 4 filings (the dominant Section 16 reporting form) must be submitted within two business days of the transaction; clusters of buys across multiple insiders within a short window are the strongest informational pattern. SEC EDGAR carries the underlying source filings for verification and additional historical depth.

Learn how insider trading is reported and how to read the data →

Frequently asked XENE insider trading questions

How active are XENE insiders right now?
Over the trailing twelve months, Xenon Pharmaceuticals Inc. (XENE) insiders made 2 buy transactions and 26 sale transactions. Net insider sentiment over the trailing twelve months tilts to the sell side (26 sales vs 2 buys). The transaction list above shows the most recent filings; each entry includes the insider's name, transaction type, share count, and per-share price.
What counts as an insider transaction?
Section 16 of the Securities Exchange Act requires officers, directors, and 10% beneficial-owner shareholders to disclose changes in their holdings via Form 3 (initial statement), Form 4 (subsequent transactions, filed within two business days), and Form 5 (annual catch-up). Insider transactions cover open-market purchases and sales, exercise of stock options, gifts, and grants. The "transaction type" field on each row distinguishes these subcategories.
Are XENE insider buys a bullish signal?
Insider purchases (Type P, made on the open market or privately; the code covers both) carry more informational weight than insider sales: an insider must commit personal capital, and the SEC scrutinizes purchases under Rule 10b5-1 for material non-public information. Sales, by contrast, are often driven by liquidity, tax planning, or pre-scheduled 10b5-1 trading plans rather than negative information. Cluster buying (multiple insiders buying within a short window) is a stronger signal than isolated buys.
How do XENE insider transactions affect options pricing?
Insider transaction data does not directly drive implied volatility, but Form 4 disclosures can move single-name IV if the size or timing is unusual (e.g. a large CEO buy ahead of an earnings window). Options markets price the marginal informational content; routine transactions under pre-scheduled plans are typically ignored. For event-driven options sizing, pair the insider transaction history with the upcoming earnings calendar.